Two experts in Charcot-Marie-Tooth (CMT), who also have the condition, recently launched the CMT Research Foundation (CMTRF) as the only nonprofit organization focused solely on delivering treatments and cures for CMT. Patrick Livney, a former chairman of Charcot-Marie-Tooth Association (CMTA), and Susan Ruediger, a former CMTA development director, have over 20 years of collective experience working with CMT researchers to deliver treatments.
CMTRF will support the most promising and effective research aimed at drug delivery by developing strategic alliances with academic and industry stakeholders. With the help of an advisory board comprised of academic, medical, and biotech experts, the CMTRF will fund translational research for all types of CMT.
“The CMT Research Foundation will play a unique role in the CMT community by limiting overhead and focusing on funding research that will help speed cures not only for various levels of CMT, but also other neurological degenerative diseases including ALS [amyotrophic lateral sclerosis] and Alzheimer’s,” said Livney.